Cardiology

How alirocumab fared for patients with polyvascular disease in a subset of the major clinical trial.

Heart disease is the greatest cause of death in women, and Wood believes female patients would better from a multidisciplinary approach.

Among participants of the EMPA-REG OUTCOME trial who experienced heart failure, empagliflozin was associated with lower rates of short-term re-hospitalization and death.

How an antibiotic envelope can address concerns of infection in cardiovascular devices.

A new study of a blood pressure-monitoring mobile app reports patients with diabetes could reach better thresholds.

What do some of the findings from one of the biggest presentations at ACC mean for the state of valve replacement care?

Why every care provider must be able to prepare for and commit to an "emergency protocol" in the face of adversity.

A 5000-plus patient study found that about 80% of young women have never been administered a lipid test.

The rate of heart attacks among patients under 40 years old has been increasing by 2% annually for the past decade.

New recommendations for prevention focus on risk factors, new therapies, and press against the popular use of aspirin as a preventive therapy.

A 3 million-plus patient longitudinal study found the drug class was no worse for amputation risks than other diabetes therapies, despite recent conflicting studies.

Now that SGLT-2 inhibitors have reached the market, how will clinicians compare their benefits in patients?

How is telehealth already influencing how some hospitals manage cardiovascular concerns?

Admissions for infective endocarditis related to intravenous drug use increased 436% from 2012-2017 at an Ohio medical center.

How advancing stent therapy options have come to bridge the gap between improving and elongating a patient's life.

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A system which rewards hospitals based on their patient readmission rates may not be considering other factors of care.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.

The Janssen therapy was significantly more beneficial for atrial fibrillation patients than warfarin.

A new study reports an independent association between air pollution and arterial inflammation—and that the former could serve as a predictor to events like stroke and myocardial infarction.

No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.

The ACC, in conjunction with the AHA and Heart Rhythm Association, released their 2019 guideline for the management of patients with atrial fibrillation.

Patients who received a flu shot had a lower rate of myocardial infarction, according to new research.

Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?

The Acticor and Rivacor brands from BIOTRONIK have become the smallest, slimmest 3 Tesla MR-conditional CRM devices on the US market.